WhaleCreep

Avidity Partners Management LP 13F holdings, Q4 2020

Hedge fundSEC filingsCompare with another fundHoldings as of 2020-12-31, filed 2021-02-16

Avidity Partners Management LP disclosed 94 US equity positions worth $3.0bn in its Q4 2020 13F filing. Its largest position is AVTR at 6.2% of the reported book, followed by ARVN and ABBV. Versus Q3 2020 it opened 52 new positions, added to 24, reduced 7 and exited 24.

$3.0bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
94
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
6.2%
Largest position
The largest single position as a share of the reported equity book.
39.7%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
41
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q3 2020: 52 new, 24 added, 7 reduced, 24 exited

50 of 94
AVTR AVANTOR INCHealthcare6.2%$185m6.57m+44%added
ARVN ARVINAS INCHealthcare5.1%$152m1.79m+33%added
ABBV ABBVIE INCHealthcare4.9%$145m1.36m−11%reduced
LLY ELI LILLY & COHealthcare4.6%$137m810,500–new
AZN ASTRAZENECA PLCHealthcare3.9%$115m2.30m–new
MRVI MARAVAI LIFESCIENCES HLDGS IHealthcare3.2%$96.7m3.45m–new
DGX QUEST DIAGNOSTICS INCHealthcare3.2%$94.4m792,100+97%added
BMRN BIOMARIN PHARMACEUTICAL INCHealthcare2.9%$87.1m992,900–new
HORIZON THERAPEUTICS PUB L no ticker–2.9%$85.5m1.17m+26%added
MRTXEUR MIRATI THERAPEUTICS INC–2.8%$83.5m380,000+38%added
NBP NOVABRIDGE BIOSCIENCESHealthcare2.5%$75.0m1.59m+19%added
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.5%$73.6m3.31m+78%added
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare2.0%$59.0m1.14m+26%added
CHNGUSD CHANGE HEALTHCARE INC–1.9%$57.5m3.08m+22%added
STTK SHATTUCK LABS INCHealthcare1.7%$49.2m938,813–new
NTRA NATERA INCHealthcare1.6%$47.8m479,800−4.7%reduced
ARNAEUR ARENA PHARMACEUTICALS INC–1.6%$47.7m621,000–new
CCXIEUR CHEMOCENTRYX INC–1.6%$46.9m757,000–new
TREUR TRILLIUM THERAPEUTICS INC–1.6%$46.9m3.19m+82%added
APLSUSD APELLIS PHARMACEUTICALS INC–1.5%$44.3m774,000+24%added
CAH CARDINAL HEALTH INCHealthcare1.5%$43.3m808,000–new
BIOHAVEN PHARMACTL HLDG CO L no ticker–1.4%$42.2m491,800−62%reduced
ORGO ORGANOGENESIS HLDGS INCHealthcare1.4%$41.6m5.52m–new
BHC BAUSCH HEALTH COS INCHealthcare1.4%$41.0m1.97m–new
KDMN KADMON HLDGS INC–1.3%$39.7m9.57m+6.0%added
XLRN ACCELERON PHARMA INC–1.3%$38.3m299,000–new
SRPT SAREPTA THERAPEUTICS INCHealthcare1.2%$37.1m217,400–new
ATHIRA PHARMA INC no ticker–1.2%$35.8m1.04m+1.7%added
MDT Medtronic PlcHealthcare1.2%$35.3m301,000+66%added
CTLTEUR CATALENT INC–1.2%$35.1m337,000+5.9%added
VRTX VERTEX PHARMACEUTICALS INCHealthcare1.2%$34.8m147,300–new
ANIK ANIKA THERAPEUTICS INCHealthcare1.1%$33.1m731,000+21%added
SIGILON THERAPEUTICS INC no ticker–1.1%$33.0m688,000–new
EXK EXACT SCIENCES CORPBasic Materials1.1%$32.7m247,000–new
EPIEUR ESSA PHARMA INC–1.0%$30.5m2.56m+23%added
CRDF CARDIFF ONCOLOGY INC–1.0%$28.9m1.61m–new
NBIX NEUROCRINE BIOSCIENCES INCHealthcare1.0%$28.8m300,000–new
ACAD ACADIA PHARMACEUTICALS INCHealthcare0.9%$28.2m527,600–new
AUPH AURINIA PHARMACEUTICALS INCHealthcare0.9%$27.7m2.00m−44%reduced
ZYME ZYMEWORKS INCHealthcare0.9%$27.3m578,100+136%added
2655787D BLUEPRINT MEDICINES CORP–0.9%$26.9m240,000–new
ATEC ALPHATEC HLDGS INCHealthcare0.9%$26.9m1.85m–new
BTAI BIOXCEL THERAPEUTICS INC–0.8%$25.3m547,000+1.7%added
ATRC ATRICURE INCHealthcare0.8%$24.9m446,600–new
COLL COLLEGIUM PHARMACEUTICAL INCHealthcare0.8%$24.8m1.24m+24%added
SHC SOTERA HEALTH COHealthcare0.6%$19.2m700,000–new
CRIS CURIS INCHealthcare0.6%$19.2m2.34m–new
SIBN SI-BONE INCHealthcare0.6%$19.1m639,884–new
DVAX DYNAVAX TECHNOLOGIES CORP–0.6%$17.8m4.00m+98%added
BLU BELLUS HEALTH INC NEW–0.6%$17.5m5.73m–new

Exited since Q3 2020

24 rows
SGENEUR SEATTLE GENETICS INC5.6%$104m
MRK MERCK & CO. INC5.1%$94.9m
BIIB BIOGEN INC4.8%$89.4m
TMO THERMO FISHER SCIENTIFIC INC2.8%$52.2m
BRISTOL-MYERS SQUIBB CO no ticker2.7%$51.0m
BAX BAXTER INTL INC2.7%$49.9m
ELV ELEVANCE HEALTH INC2.6%$47.4m
QDELUSD QUIDEL CORP2.1%$38.8m
BSX BOSTON SCIENTIFIC CORP2.0%$37.0m
IOVA IOVANCE BIOTHERAPEUTICS INC1.4%$26.3m
HUM HUMANA INC1.1%$21.3m
AMARIN CORP PLC no ticker1.0%$19.0m
EXEL EXELIXIS INC1.0%$18.8m
AKBA AKEBIA THERAPEUTICS INC1.0%$18.4m
ADAPY ADAPTIMMUNE THERAPEUTICS PLC0.9%$16.6m
BNTX BIONTECH SE0.8%$14.3m
MERSANA THERAPEUTICS INC no ticker0.8%$14.1m
IDYA IDEAYA BIOSCIENCES INC0.7%$13.2m
AXSM AXSOME THERAPEUTICS INC.0.5%$8.4m
ACIU AC IMMUNE SA0.4%$7.6m
CLVSEUR CLOVIS ONCOLOGY INC0.3%$5.8m
ARYA SCIENCES ACQUISTION CO no ticker0.3%$5.4m
PMVP PMV PHARMACEUTICALS INC0.3%$5.3m
BLIUSD PHENOMEX INC0.1%$1.9m

Sector mix

  • Healthcare66.9%
  • Unclassified32.0%
  • Basic Materials1.1%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters